Skip to main content
OpenTrials
Completed

NCT Number: NCT05217888

The Sentinel Registry

This registry is to evaluate procedural outcomes and safety outcomes of cerebral protection devices during transfemoral TAVR in real-world clinical practice.

The data from this registry will be compared with the extracted data from the TP TAVR registry(NCT038262664) using Propensity Score Matching.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Bucheon Sejong Hospital, Bucheon-si, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 19 and more
  • Undergoing TAVR with the use of SENTINEL embolic protection device
  • Higher risk of cerebrovascular embolic events (any of the followings)
  • Bicuspid aortic valve
  • Calcified lesion or atherosclerosis in the ascending aorta and/or aortic arch
  • Heavy calcified aortic valve (Ca. volume > 500)
  • Chronic kidney disease
  • Prior stroke
  • Stroke risk is strongly anticipated by attending physicians
  • Compatible carotid and brachiocephalic artery anatomy for SENTINEL device as determined by Multi-Slice Computed Tomography scan or equivalent imaging modality
  • Agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Exclusion criteria

  • Vasculature in the right extremity precluding radial or brachial access
  • Excessive tortuosity in the right radial/brachial/subclavian artery preventing Sentinel System access and insertion
  • Inadequate circulation to the right extremity as evidenced by signs of artery occlusion (modified Allen's test) or absence of radial/brachial pulse
  • Hemodialysis shunt, graft, or arterio-venous fistula involving the upper extremity vasculature
  • Symptomatic or asymptomatic severe occlusive carotid disease requiring concomitant carotid endarterectomy/stenting
  • Undergone carotid stenting or carotid endarterectomy within the previous 6 weeks
  • Concurrent medical condition with a life expectancy of less than 1 year

Treatment and study plan

Sentinel

Device

cerebral protection devices during transfemoral transcatheter aortic valve replacement

Primary outcomes

  1. The rate of procedural success

    Time frame: 1 month

    Procedural Success: Sentinel system acute delivery and retrieval (categorized as successful deployment of both filters, 1 filter, or no filter and retrieval of the system)

    Procedural outcomes

    • Procedure time(min)
    • Positioning time
    • Total fluoroscopy time
    • Total contrast used
    • Total procedure index time
    • Sentinel access site vascular complications related to the procedure (major and minor)

Secondary outcomes

  1. The event rate of death from any cause

    Time frame: 1 month

  2. The event rate of cardiac death

    Time frame: 1 month

  3. The event rate of stroke

    Time frame: 1 month

  4. The event rate of myocardial infarction

    Time frame: 1 month

  5. The event rate of systemic embolic event

    Time frame: 1 month

  6. The event rate of vascular complication

    Time frame: 1 month

  7. The event rate of bleeding

    Time frame: 1 month

  8. The event rate of acute kidney injury

    Time frame: 1 month

  9. The event rate of repeat hospitalization

    Time frame: 1 month

Sponsors and collaborators

Lead sponsor

Duk-Woo Park, MD

Other

Collaborators

  • Boston Scientific Corporation
  • CardioVascular Research Foundation, Korea

Registry information

Official study title

Evaluation of Procedural Outcomes and Safety of Cerebral Embolic Protection Device for Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement in Routine Clinical Practice, A Multicenter, Prospective Observational Study

Acronym: Sentinel

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Feb 1, 2022
Registry last updated
Jun 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.